You are currently viewing Ciloa at DDIP 2026 in Basel

Robert Mamoun, CEO of Ciloa, will speak at the Drug Discovery Innovation Programme (DDIP) on 29–30 September 2026 at the Mövenpick Hotel in Basel. The talk, “Adiponectin-EVs: Next-Generation Metabolic Disease Therapy,” will present APN-EV, our biomimetic adiponectin therapeutic candidate produced through the patented EVENGI™ platform. It is GMP-ready, scalable and stable at 4 °C.

Attending DDIP? Contact us to meet in Basel.